Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 9 | Rare Historical Photos

PPE Medpro fails to meet deadline to repay Government almost £122m after ruling

Mrs Justice Cockerill previously ruled that PPE Medpro had breached a contract for millions of surgical gowns during the coronavirus pandemic.

Evening Standard

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

Benzinga

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.

Benzinga

Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs

As the largest publicly traded U.S. healthcare enterprise, Eli Lilly Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately $960 in late summer of last year. However,…

Benzinga

Chronic Drug Shortages Frustrate EU Pharmacists, Patients

At a drug wholesaler warehouse in Belgium, shelves are emptier than they used to be.

International Business Times

Prescription drug coverage options are shrinking for Medicare shoppers

Fewer choices may be on the menu again as Medicare patients shop for prescription coverage this fall

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

TikTok influencers fuelling parallel market for unlicensed weight-loss drug

Guardian finds a thriving trade on Telegram for retatrutide, which is still in clinical trials and illegal to sell

The Guardian - UK

AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs

Company will sell some medicines at a discount to government’s Medicaid health plan in exchange for tariff relief

The Guardian - US

PPE Medpro partners willing to discuss ‘possible settlement’ of Covid gowns case

The Baroness Michelle Mone-linked company was ordered to pay back nearly £122 million due to a breach of contract

Evening Standard

UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments

UK ministers are preparing to increase the amount the National Health Service pays pharmaceutical firms for medicines by up to 25%, following weeks of intensive discussions with the Trump administration and drugmakers.

Benzinga

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

Among the recent momentum standouts in the biotechnology sector, four stocks have drawn considerable investor attention, entering the top 10th percentile of momentum-ranked stocks based on decisive week-on-week percentile gains.

Benzinga

Why Did Biodexa Pharmaceuticals' Stock Drop After-Hours Despite Big Gain During Regular Trading?

Biodexa Pharmaceuticals PLC-ADR (NASDAQ:BDRX) saw its stock fall 3.67% to $10.50 during after-hours trading on Thursday.

Benzinga

4 Stocks In The Same Sector Just Made A Huge Leap In Momentum Rankings

Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names have been picking up steam as the market rally broadens and major indexes continue to reach new highs. Here’s a look at four stocks flashing strong momentum signals.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

The Trump administration is reportedly planning to exclude imported generic drugs from tariffs.

Benzinga

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement.

Benzinga

Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug

Zenas BioPharma Inc. (NASDAQ:ZBIO) and InnoCare Pharma Ltd. on Wednesday announced a license agreement granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology.

Benzinga

TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout

TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced on Wednesday that it has entered a definitive agreement to acquire Polynoma LLC, a privately held biotechnology firm focused on immuno-oncology.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

Kiplinger

Major Insurers Scale Back Medicare Advantage and Part D Plans for 2026

Beneficiaries enrolled in Medicare Advantage and Part D prescription drug plans might be losing their plan as UnitedHealthcare, Humana, and Aetna (CVS Health) scale back offerings for 2026.

Benzinga

Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?

Processa Pharmaceuticals Inc. (NASDAQ:PCSA) shares soared 37.5% to $0.50 during after-hours trading on Tuesday.

Benzinga

Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites

Novo Nordisk A/S (NYSE:NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site in North Carolina, part of a global restructuring effort under new CEO Mike Doustdar.

Benzinga

4 Biotech Stocks Seeing Explosive Momentum Gains

A wider range of stocks have been gaining traction lately as major indexes push toward record highs. The SPDR SP Biotech ETF (NYSE:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the…

Benzinga

AMD's OpenAI Deal Could Spark A New AI Arms Race With Nvidia

Advanced Micro Devices Inc.’s (NASDAQ:AMD) multi-year deal with OpenAI could unlock $135 billion in revenue and mount a serious challenge to Nvidia Corp.’s (NASDAQ:NVDA) long-standing dominance, according to Goldman Sachs.

Benzinga

EXCLUSIVE: Envoy Medical Cuts Capital Needs After FDA Approval For Final Trial Stage Of Cochlear Implant Trial

Envoy Medical Inc. (NASDAQ:COCH) announced on Tuesday that it has received U.S. Food and Drug Administration (FDA) approval to expand its pivotal clinical trial for the fully implanted Acclaim cochlear implant to the final stage, based on promising three-month data from the first 10 patients.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.